Randomized trial · people

MK-677 raised bone turnover markers in adults 65 and older

Checked against the paper Randomized trialPublished by PepVault

The takeaway

MK-677 sped up markers of both bone breakdown and bone building in older adults over a few weeks, but this paper does not show whether bones got stronger.

Kind
Randomized trial
Studied in
People
Number studied
187
Published
1999
Journal
J Bone Miner Res

What they tested

The team tested whether taking MK-677 by mouth every day changes IGF-I, a growth-related hormone in the blood, and markers of bone turnover in older adults.

How the study was done

A set of randomized, double-blind, placebo-controlled trials (placebo, a dummy pill) in 187 adults aged 65 or older, lasting 2 to 9 weeks. The earlier trials enrolled healthy older adults, and the last one enrolled 105 older adults who met set criteria for functional impairment.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In healthy older adults, 2 weeks in the 10 mg and 25 mg arms raised urine NTX, a marker of bone breakdown, by 10% and 17% compared with placebo. In another healthy group given 25 mg and then 50 mg, serum osteocalcin, a marker of bone building, rose by 8%, and IGF-I rose by 55-94% across these healthy-adult trials. In functionally impaired adults treated for 9 weeks, osteocalcin rose 29.4%, BSAP (bone-specific alkaline phosphatase, another bone-building marker) rose 10.4%, and urine NTX rose 22.6% versus placebo. The rise in osteocalcin tracked with the rise in IGF-I (r = 0.37).

What it doesn’t show

These were short trials of 2 to 9 weeks with small groups, and they measured only blood and urine markers. They did not test bone density, bone strength or fractures.

The paper

Murphy et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999.

The compound

More studies on MK-677

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo